Sarilumab improves quality of life, patient-reported outcomes in polymyalgia rheumatica

Patients with polymyalgia rheumatica who received sarilumab and a 14-week glucocorticoid taper reported improved outcomes and quality of life vs. placebo with a 52-week steroid taper, according to data published in The Lancet Rheumatology.“Based on a relatively small trial in patients with relapsing PMR, sarilumab is now approved for those who have not responded adequately to